The MedTech Pricing Decision Most Teams Get Wrong
When MedTech companies evaluate pricing architecture, many teams ask, “Should we run MaxDiff or Conjoint?” The better question is: “What decision must this model support?” Both methods are powerful, but they answer different strategic questions. Choosing the wrong one creates elegant analysis with low decision utility.
MaxDiff: Best for Priority Structure
MaxDiff (best-worst scaling) is ideal when teams need a clean hierarchy of value drivers. It excels in early strategy phases where the objective is to identify which features, outcomes, or service elements stakeholders value most relative to alternatives.
- Strength: robust discrimination across many attributes.
- Output: clear relative importance ranking.
- Use case: message hierarchy, value proposition shaping, and early packaging strategy.
Conjoint: Best for Trade-Off and Price Simulation
Conjoint analysis is superior when teams need to estimate willingness-to-pay and market-share effects under realistic product-price configurations. It captures trade-offs directly and supports scenario modeling for commercial planning.
- Strength: simulates decision behavior under constraint.
- Output: utility estimates, price elasticity, preference shares.
- Use case: final pricing strategy, offer design, and launch scenario simulation.
Where Each Method Fails if Misapplied
- MaxDiff misuse: treating rank outputs as direct pricing elasticity inputs.
- Conjoint misuse: overloading respondents with too many attributes and unrealistic task designs.
- Both misuse: skipping segmentation and assuming one global utility structure.
Recommended MedTech Workflow
- Run MaxDiff to establish high-confidence attribute hierarchy.
- Use findings to reduce conjoint attribute complexity.
- Execute conjoint with realistic product and reimbursement contexts.
- Model outputs by segment: hospital procurement, specialist prescribers, and payer-influenced users.
Bottom-Line Recommendation
If your question is “What matters most?” start with MaxDiff. If your question is “What can we price and still win?” use Conjoint. In many MedTech categories, the highest-confidence strategy combines both sequentially.
For implementation patterns in GCC healthcare markets, read our guide on quantitative healthcare market research.
Author Bio: Written by Mohammad Alsaadany, healthcare market research specialist with 15+ years in pharmaceutical and MedTech strategy. LinkedIn: linkedin.com/in/mohammad-alsaadany.